Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,982
archived clinical trials in
Endocrine

Reduction of Nocturnal Hypoglycemia and Hyperglycemia in the Home Using Predictive Algorithms, Pump Suspension, and Insulin Dosing in Children and Young Adolescents
Reduction of Nocturnal Hypoglycemia and Hyperglycemia in the Home Using Predictive Algorithms, Pump Suspension, and Insulin Dosing in Children and Young Adolescents (PHM3)
Status: Enrolling
Updated:  5/9/2017
824
mi
from 91732
Aurora, CO
Reduction of Nocturnal Hypoglycemia and Hyperglycemia in the Home Using Predictive Algorithms, Pump Suspension, and Insulin Dosing in Children and Young Adolescents
Reduction of Nocturnal Hypoglycemia and Hyperglycemia in the Home Using Predictive Algorithms, Pump Suspension, and Insulin Dosing in Children and Young Adolescents (PHM3)
Status: Enrolling
Updated: 5/9/2017
Barbara Davis Center for Childhood Diabetes
824
mi
from 91732
Aurora, CO
Click here to add this to my saved trials
Determine How Consumption of Dairy Fat as Cheese Influences Inflammation-Phase 2
Effects of Dairy Fat on Postprandial Inflammation- Phase 2
Status: Enrolling
Updated:  5/18/2017
372
mi
from 91732
Davis, CA
Determine How Consumption of Dairy Fat as Cheese Influences Inflammation-Phase 2
Effects of Dairy Fat on Postprandial Inflammation- Phase 2
Status: Enrolling
Updated: 5/18/2017
USDA-Western Human Nutrition Research Center
372
mi
from 91732
Davis, CA
Click here to add this to my saved trials
Determine How Consumption of Dairy Fat Fractions Rich in Phospholipids and Proteins Influence Inflammation in the Fed State-Phase 1
Effects of Dairy Fat on Postprandial Inflammation- Phase 2
Status: Enrolling
Updated:  5/18/2017
372
mi
from 91732
Davis, CA
Determine How Consumption of Dairy Fat Fractions Rich in Phospholipids and Proteins Influence Inflammation in the Fed State-Phase 1
Effects of Dairy Fat on Postprandial Inflammation- Phase 2
Status: Enrolling
Updated: 5/18/2017
USDA-Western Human Nutrition Research Center
372
mi
from 91732
Davis, CA
Click here to add this to my saved trials
28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men
A Phase II, 28-Day, Randomized, Parallel-Group, Open-Label Study Evaluating the Efficacy and Safety of Twice Daily Oral Doses of Testosterone (150-400mg) Co-administered With 0.25mg Dutasteride Compared With 400mg Testosterone Alone and 0.25mg Dutasteride Alone in the Treatment of Hypogonadism
Status: Enrolling
Updated:  5/25/2017
22
mi
from 91732
Torrance, CA
28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men
A Phase II, 28-Day, Randomized, Parallel-Group, Open-Label Study Evaluating the Efficacy and Safety of Twice Daily Oral Doses of Testosterone (150-400mg) Co-administered With 0.25mg Dutasteride Compared With 400mg Testosterone Alone and 0.25mg Dutasteride Alone in the Treatment of Hypogonadism
Status: Enrolling
Updated: 5/25/2017
GSK Investigational Site
22
mi
from 91732
Torrance, CA
Click here to add this to my saved trials
28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men
A Phase II, 28-Day, Randomized, Parallel-Group, Open-Label Study Evaluating the Efficacy and Safety of Twice Daily Oral Doses of Testosterone (150-400mg) Co-administered With 0.25mg Dutasteride Compared With 400mg Testosterone Alone and 0.25mg Dutasteride Alone in the Treatment of Hypogonadism
Status: Enrolling
Updated:  5/25/2017
1813
mi
from 91732
Louisville, KY
28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men
A Phase II, 28-Day, Randomized, Parallel-Group, Open-Label Study Evaluating the Efficacy and Safety of Twice Daily Oral Doses of Testosterone (150-400mg) Co-administered With 0.25mg Dutasteride Compared With 400mg Testosterone Alone and 0.25mg Dutasteride Alone in the Treatment of Hypogonadism
Status: Enrolling
Updated: 5/25/2017
GSK Investigational Site
1813
mi
from 91732
Louisville, KY
Click here to add this to my saved trials
28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men
A Phase II, 28-Day, Randomized, Parallel-Group, Open-Label Study Evaluating the Efficacy and Safety of Twice Daily Oral Doses of Testosterone (150-400mg) Co-administered With 0.25mg Dutasteride Compared With 400mg Testosterone Alone and 0.25mg Dutasteride Alone in the Treatment of Hypogonadism
Status: Enrolling
Updated:  5/25/2017
2301
mi
from 91732
Baltimore, MD
28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men
A Phase II, 28-Day, Randomized, Parallel-Group, Open-Label Study Evaluating the Efficacy and Safety of Twice Daily Oral Doses of Testosterone (150-400mg) Co-administered With 0.25mg Dutasteride Compared With 400mg Testosterone Alone and 0.25mg Dutasteride Alone in the Treatment of Hypogonadism
Status: Enrolling
Updated: 5/25/2017
GSK Investigational Site
2301
mi
from 91732
Baltimore, MD
Click here to add this to my saved trials
28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men
A Phase II, 28-Day, Randomized, Parallel-Group, Open-Label Study Evaluating the Efficacy and Safety of Twice Daily Oral Doses of Testosterone (150-400mg) Co-administered With 0.25mg Dutasteride Compared With 400mg Testosterone Alone and 0.25mg Dutasteride Alone in the Treatment of Hypogonadism
Status: Enrolling
Updated:  5/25/2017
2198
mi
from 91732
Durham, NC
28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men
A Phase II, 28-Day, Randomized, Parallel-Group, Open-Label Study Evaluating the Efficacy and Safety of Twice Daily Oral Doses of Testosterone (150-400mg) Co-administered With 0.25mg Dutasteride Compared With 400mg Testosterone Alone and 0.25mg Dutasteride Alone in the Treatment of Hypogonadism
Status: Enrolling
Updated: 5/25/2017
GSK Investigational Site
2198
mi
from 91732
Durham, NC
Click here to add this to my saved trials
28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men
A Phase II, 28-Day, Randomized, Parallel-Group, Open-Label Study Evaluating the Efficacy and Safety of Twice Daily Oral Doses of Testosterone (150-400mg) Co-administered With 0.25mg Dutasteride Compared With 400mg Testosterone Alone and 0.25mg Dutasteride Alone in the Treatment of Hypogonadism
Status: Enrolling
Updated:  5/25/2017
1184
mi
from 91732
San Antonio, TX
28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men
A Phase II, 28-Day, Randomized, Parallel-Group, Open-Label Study Evaluating the Efficacy and Safety of Twice Daily Oral Doses of Testosterone (150-400mg) Co-administered With 0.25mg Dutasteride Compared With 400mg Testosterone Alone and 0.25mg Dutasteride Alone in the Treatment of Hypogonadism
Status: Enrolling
Updated: 5/25/2017
GSK Investigational Site
1184
mi
from 91732
San Antonio, TX
Click here to add this to my saved trials
28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men
A Phase II, 28-Day, Randomized, Parallel-Group, Open-Label Study Evaluating the Efficacy and Safety of Twice Daily Oral Doses of Testosterone (150-400mg) Co-administered With 0.25mg Dutasteride Compared With 400mg Testosterone Alone and 0.25mg Dutasteride Alone in the Treatment of Hypogonadism
Status: Enrolling
Updated:  5/25/2017
963
mi
from 91732
Seattle, WA
28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men
A Phase II, 28-Day, Randomized, Parallel-Group, Open-Label Study Evaluating the Efficacy and Safety of Twice Daily Oral Doses of Testosterone (150-400mg) Co-administered With 0.25mg Dutasteride Compared With 400mg Testosterone Alone and 0.25mg Dutasteride Alone in the Treatment of Hypogonadism
Status: Enrolling
Updated: 5/25/2017
GSK Investigational Site
963
mi
from 91732
Seattle, WA
Click here to add this to my saved trials
Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism
A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety and Tolerability of Single Ascending Doses of KAI-4169 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated:  5/26/2017
17
mi
from 91732
Cypress, CA
Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism
A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety and Tolerability of Single Ascending Doses of KAI-4169 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated: 5/26/2017
Clinical Research Facility
17
mi
from 91732
Cypress, CA
Click here to add this to my saved trials
Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism
A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety and Tolerability of Single Ascending Doses of KAI-4169 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated:  5/26/2017
1401
mi
from 91732
Shreveport, LA
Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism
A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety and Tolerability of Single Ascending Doses of KAI-4169 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated: 5/26/2017
Clinical Research Facility
1401
mi
from 91732
Shreveport, LA
Click here to add this to my saved trials
Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism
A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety and Tolerability of Single Ascending Doses of KAI-4169 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated:  5/26/2017
1357
mi
from 91732
Houston, TX
Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism
A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety and Tolerability of Single Ascending Doses of KAI-4169 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated: 5/26/2017
Clinical Research Facility
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism
A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety and Tolerability of Single Ascending Doses of KAI-4169 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated:  5/26/2017
7198
mi
from 91732
Brisbane,
Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism
A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety and Tolerability of Single Ascending Doses of KAI-4169 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated: 5/26/2017
7198
mi
from 91732
Brisbane,
Click here to add this to my saved trials
Meal Patterning on Weight Loss With Changes to Body Comp, Muscle and Metabolic Health
Effects of Dietary Protein Patterning on wt Loss and Resistance Training-induced Changes in Body Comp, Skeletal Muscle, and Indices of Metabolic Syndrome
Status: Enrolling
Updated:  5/31/2017
1755
mi
from 91732
West Lafayette, IN
Meal Patterning on Weight Loss With Changes to Body Comp, Muscle and Metabolic Health
Effects of Dietary Protein Patterning on wt Loss and Resistance Training-induced Changes in Body Comp, Skeletal Muscle, and Indices of Metabolic Syndrome
Status: Enrolling
Updated: 5/31/2017
Purdue University
1755
mi
from 91732
West Lafayette, IN
Click here to add this to my saved trials
Effects of Omega-3 Fatty Acids on Markers of Inflammation
Effects of Plant and Marine Omega-3 (w-3) Fatty Acids on Inflammatory Markers In Insulin Resistant Adults
Status: Enrolling
Updated:  5/31/2017
328
mi
from 91732
Stanford, CA
Effects of Omega-3 Fatty Acids on Markers of Inflammation
Effects of Plant and Marine Omega-3 (w-3) Fatty Acids on Inflammatory Markers In Insulin Resistant Adults
Status: Enrolling
Updated: 5/31/2017
Stanford University School of Medicine
328
mi
from 91732
Stanford, CA
Click here to add this to my saved trials
Thyroid Disease Serum Repository
Thyroid Disease Serum Repository
Status: Enrolling
Updated:  6/1/2017
1461
mi
from 91732
Little Rock, AR
Thyroid Disease Serum Repository
Thyroid Disease Serum Repository
Status: Enrolling
Updated: 6/1/2017
University of Arkansas for Medical Sciences
1461
mi
from 91732
Little Rock, AR
Click here to add this to my saved trials
Effects and Mechanisms of Melatonin on Blood Pressure, Insulin Resistance, and Platelets
Effects and Mechanisms of Melatonin on Blood Pressure, Insulin Resistance, and Platelets
Status: Enrolling
Updated:  6/5/2017
2375
mi
from 91732
Philadelphia, PA
Effects and Mechanisms of Melatonin on Blood Pressure, Insulin Resistance, and Platelets
Effects and Mechanisms of Melatonin on Blood Pressure, Insulin Resistance, and Platelets
Status: Enrolling
Updated: 6/5/2017
Thomas Jefferson University
2375
mi
from 91732
Philadelphia, PA
Click here to add this to my saved trials
Obstructive Sleep Apnea and Metabolic Health
Obstrutive Sleep Apnea: is it a Biomarker of Metabolically Healthy vs. Unhealthy Obese
Status: Enrolling
Updated:  6/6/2017
1959
mi
from 91732
Columbus, OH
Obstructive Sleep Apnea and Metabolic Health
Obstrutive Sleep Apnea: is it a Biomarker of Metabolically Healthy vs. Unhealthy Obese
Status: Enrolling
Updated: 6/6/2017
Ohio State University
1959
mi
from 91732
Columbus, OH
Click here to add this to my saved trials
Weight Loss Diet Study: Low Carb vs Low Fat
Weight Loss Diet Study: Low Carbohydrate vs. Low Fat and Insulin Resistance Status
Status: Enrolling
Updated:  6/7/2017
328
mi
from 91732
Stanford, CA
Weight Loss Diet Study: Low Carb vs Low Fat
Weight Loss Diet Study: Low Carbohydrate vs. Low Fat and Insulin Resistance Status
Status: Enrolling
Updated: 6/7/2017
Stanford University School of Medicine
328
mi
from 91732
Stanford, CA
Click here to add this to my saved trials
The Metabolic Effects of Short-term Walnut Consumption in Subjects With the Metabolic Syndrome
The Metabolic Effects of Short-term Walnut Consumption in Subjects With the Metabolic Syndrome
Status: Enrolling
Updated:  6/21/2017
2578
mi
from 91732
Boston, MA
The Metabolic Effects of Short-term Walnut Consumption in Subjects With the Metabolic Syndrome
The Metabolic Effects of Short-term Walnut Consumption in Subjects With the Metabolic Syndrome
Status: Enrolling
Updated: 6/21/2017
Beth Israel Deaconess Medical Center
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
Effect of a Grape Seed Extract (GSE) on Insulin Resistance
Effect of a Grape Seed Extract (GSE) on Insulin Resistance
Status: Enrolling
Updated:  6/26/2017
359
mi
from 91732
Mather, CA
Effect of a Grape Seed Extract (GSE) on Insulin Resistance
Effect of a Grape Seed Extract (GSE) on Insulin Resistance
Status: Enrolling
Updated: 6/26/2017
VA Hospital, Mather
359
mi
from 91732
Mather, CA
Click here to add this to my saved trials
Insulin Resistance in Nonalcoholic Fatty Liver Disease: A Case Control Study
Insulin Resistance in Nonalcoholic Fatty Liver Disease: A Case Control Study
Status: Enrolling
Updated:  7/10/2017
2203
mi
from 91732
Durham, NC
Insulin Resistance in Nonalcoholic Fatty Liver Disease: A Case Control Study
Insulin Resistance in Nonalcoholic Fatty Liver Disease: A Case Control Study
Status: Enrolling
Updated: 7/10/2017
Duke Univ Med Ctr
2203
mi
from 91732
Durham, NC
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
1784
mi
from 91732
Birmingham, AL
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
1784
mi
from 91732
Birmingham, AL
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
6
mi
from 91732
Alhambra, CA
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
6
mi
from 91732
Alhambra, CA
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
7
mi
from 91732
Azusa, CA
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
7
mi
from 91732
Azusa, CA
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
106
mi
from 91732
Bakersfield, CA
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
106
mi
from 91732
Bakersfield, CA
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
12
mi
from 91732
Cudahy, CA
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
12
mi
from 91732
Cudahy, CA
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
31
mi
from 91732
Granada Hills, CA
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
31
mi
from 91732
Granada Hills, CA
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
13
mi
from 91732
Los Angeles, CA
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
13
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
13
mi
from 91732
Los Angeles, CA
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
13
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
25
mi
from 91732
Northridge, CA
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
25
mi
from 91732
Northridge, CA
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
31
mi
from 91732
Riverside, CA
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
31
mi
from 91732
Riverside, CA
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
45
mi
from 91732
Simi Valley, CA
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
45
mi
from 91732
Simi Valley, CA
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
369
mi
from 91732
Vacaville, CA
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
369
mi
from 91732
Vacaville, CA
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
7
mi
from 91732
Whittier, CA
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
7
mi
from 91732
Whittier, CA
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
825
mi
from 91732
Aurora, CO
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
825
mi
from 91732
Aurora, CO
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
819
mi
from 91732
Westminster, CO
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
819
mi
from 91732
Westminster, CO
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
2455
mi
from 91732
Stamford, CT
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
2455
mi
from 91732
Stamford, CT
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
2321
mi
from 91732
Miami, FL
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
2321
mi
from 91732
Miami, FL
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
2128
mi
from 91732
Ocala, FL
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
2128
mi
from 91732
Ocala, FL
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
2306
mi
from 91732
Pembroke Pines, FL
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
2306
mi
from 91732
Pembroke Pines, FL
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
2136
mi
from 91732
Tampa, FL
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
2136
mi
from 91732
Tampa, FL
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
2053
mi
from 91732
Augusta, GA
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
2053
mi
from 91732
Augusta, GA
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
2019
mi
from 91732
Dublin, GA
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
2019
mi
from 91732
Dublin, GA
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
664
mi
from 91732
Meridian, ID
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
664
mi
from 91732
Meridian, ID
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
1641
mi
from 91732
Highland Park, IL
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
1641
mi
from 91732
Highland Park, IL
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
1741
mi
from 91732
Merrillville, IN
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
1741
mi
from 91732
Merrillville, IN
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
1766
mi
from 91732
Michigan City, IN
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
1766
mi
from 91732
Michigan City, IN
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
1182
mi
from 91732
Wichita, KA
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
1182
mi
from 91732
Wichita, KA
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
1589
mi
from 91732
Baton Rouge, LA
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
1589
mi
from 91732
Baton Rouge, LA
Click here to add this to my saved trials